Literature DB >> 8606106

Changes in the peripheral blood T-Cell receptor V beta repertoire in vivo and in vitro during shigellosis.

D Islam1, B Wretlind, A A Lindberg, B Christensson.   

Abstract

A sequential activation of T cells in peripheral blood during shigello sis has been observer (D. Islam, P.K. Bradham, A. A. Lindberg, and B. Christensson, Infect. Immun 63:2941-2949, 1995). To further investigate the cellular response during the course of Shigella infection, changes in the T-cell receptor (TCR) repertoire in the subsets in blood in patients during shigellosis was that Shigella antigens may modulate the function of T cells carrying TCRs capable of recognizing Shigella-specific epitopes or superantigens. Such a selective preference for T cells expressing certain TCR Vbeta types could lead to the expansion or deletion of these T cells. In the present study of 27 adult male Bangladeshi patients with dysentery (14 cases caused by Shigella Dysenteriae 1 and 13 cases caused by Shigella flexneri), the changes in the TCR Vbeta repertoire of peripheral blood CD4+ and CD8+ T-cell subsets have been analyzed with a panel of nine anti-Vbeta monoclonal antibodies by flow cytometry. Twenty healthy males from Bangladesh and 20 healthy males from Sweden served as controls. Compared with the Bangladeshi controls, the patients had an increased frequency of CD4+T cells expression Vbeta2, Vbeta3, and Vbeta17, with a maximum at day 7 after the onset of disease. The frequency of CD4+T cells expressing Vbeta5.1 was increased only in patients with S. flexneri infection. Peripheral blood T cells from Shigella-infected patients also responded to in vitro stimulation in a TCR Vbeta-specific manner. Stimulation with heat-killed S. dysenteriae 1 and Shiga toxin enhanced the frequency of cells expressing Vbeta2, Vbeta3, Vbeta5.1, Vbeta13.6, and Vbeta17, especially in samples obtained at day 7. The enhanced frequency of cells expressing Vbeta2, Vbeta3, Vbeta5.1, and Vbeta17 found both in in vivo and in vitro could suggest that in shigellosis antigens or superantigens are presented to the immune system and preferentially activate certain TCR Vbeta types in T-cell subsets. The kinetics of the change in the TCR Vbeta repertoire in blood during shigellosis may indicate that following local activation, the antigen activated T cells can be retrieved in the blood and restimulated in vitro. If confirmed by parallel analysis of T cells in the gut and blood by TCR sequence analysis, the possibility suggested by our findings would facilitate further analysis of the role of cell-mediated immune responses in the pathogenesis of and protection against Shigella infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606106      PMCID: PMC173931          DOI: 10.1128/iai.64.4.1391-1399.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Staphylococcal enterotoxin B activates purified NK cells to secrete IFN-gamma but requires T lymphocytes to augment NK cytotoxicity.

Authors:  J A D'Orazio; G W Burke; J Stein-Streilein
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

2.  Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells.

Authors:  E M Beckman; S A Porcelli; C T Morita; S M Behar; S T Furlong; M B Brenner
Journal:  Nature       Date:  1994-12-15       Impact factor: 49.962

Review 3.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain.

Authors:  A Geluk; X T Fu; K E van Meijgaarden; Y Y Jansen; R R De Vries; R W Karr; T H Ottenhoff
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

5.  Endotoxin and lipid A stimulate proliferation of human T cells in the presence of autologous monocytes.

Authors:  T Mattern; A Thanhäuser; N Reiling; K M Toellner; M Duchrow; S Kusumoto; E T Rietschel; M Ernst; H Brade; H D Flad
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

6.  Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen.

Authors:  J E McCormack; J E Callahan; J Kappler; P C Marrack
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

7.  Immunopathological patterns in the rectal mucosa of patients with shigellosis: expression of HLA-DR antigens and T-lymphocyte subsets.

Authors:  R Raqib; F P Reinholt; P K Bardhan; A Kärnell; A A Lindberg
Journal:  APMIS       Date:  1994-05       Impact factor: 3.205

8.  T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients.

Authors:  J Grunewald; O Olerup; U Persson; M B Ohrn; H Wigzell; A Eklund
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  TCR V beta family repertoire and T cell activation markers in Kawasaki disease.

Authors:  B A Pietra; J De Inocencio; E H Giannini; R Hirsch
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

10.  Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma.

Authors:  R Raqib; B Wretlind; J Andersson; A A Lindberg
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

View more
  11 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Adaptive immune responses during Shigella dysenteriae type 1 infection: an in vitro stimulation with 57 kDa major antigenic OMP in the presence of anti-CD3 antibody.

Authors:  Ashim Kumar Bagchi; Ajoy Kumar Sinha; Rushita Adhikari; Joydeep Mukherjee
Journal:  Mol Cell Biochem       Date:  2009-11-14       Impact factor: 3.396

Review 3.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

Review 4.  The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies.

Authors:  D J Philpott; J D Edgeworth; P J Sansonetti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

5.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Antigen-specific CD8(+) T cells fail to respond to Shigella flexneri.

Authors:  Stephanie P Jehl; Amy M Doling; Kara S Giddings; Armelle Phalipon; Philippe J Sansonetti; Marcia B Goldberg; Michael N Starnbach
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

7.  Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires.

Authors:  Rosângela Salerno-Gonçalves; Rezwanul Wahid; Marcelo B Sztein
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

8.  Persistence of mucosal mast cells and eosinophils in Shigella-infected children.

Authors:  Rubhana Raqib; Pricila Khan Moly; Protim Sarker; Firdausi Qadri; Nurul Haque Alam; Minnie Mathan; Jan Andersson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

9.  T cell activation profiles in Kawasaki syndrome.

Authors:  P A Brogan; V Shah; L A Clarke; M J Dillon; N Klein
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

10.  Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics.

Authors:  Courtney L Davis; Rezwanul Wahid; Franklin R Toapanta; Jakub K Simon; Marcelo B Sztein; Doron Levy
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.